Reply to L. Marandino et al

Abstract

We thank Marandino et al 1 and agree that cognitive function is important and complex in men with metastatic, hormone-sensitive prostate cancer. Cognitive decline increases with age, as does the incidence of metastatic prostate cancer, and has been associated with a diagnosis of cancer, androgen deprivation therapy, early generation antiandrogens, novel androgen signaling inhibitors, and chemotherapy. 2 ENZAMET provides unique information about self-ratings of cognitive function and other aspects of health-related quality of life (HRQoL) in men receiving these treatments for metastatic, hormone-sensitive prostate cancer. 3

Reply to L. Marandino et al

“…As patients with prostate cancer receive NHT such as enzalutamide increasingly early in the disease history and for longer periods of time, accurately capturing their impact on QOL outcomes such as cognitive function is of increasing importance. We appreciate the efforts by Stockler et al 10 to measure the impact of treatment with enzalutamide on cognitive function, as well as the constructive letter by Marandino et al 3 highlighting potential directions to continue to improve our ability to measure cognitive function in future prostate cancer clinical trials.…”